Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 5,600 shares, a drop of 66.7% from the December 15th total of 16,800 shares. Based on an average trading volume of 133,400 shares, the days-to-cover ratio is currently 0.0 days.
Institutional Trading of Kazia Therapeutics
An institutional investor recently bought a new position in Kazia Therapeutics stock. MAI Capital Management bought a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics at the end of the most recent reporting period. 30.89% of the stock is owned by institutional investors and hedge funds.
Kazia Therapeutics Trading Down 4.4 %
Shares of NASDAQ KZIA traded down $0.07 during mid-day trading on Monday, reaching $1.51. 82,278 shares of the company’s stock were exchanged, compared to its average volume of 134,068. The firm has a 50-day moving average price of $4.10 and a two-hundred day moving average price of $4.11. Kazia Therapeutics has a 52 week low of $1.42 and a 52 week high of $15.80.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
Read More
- Five stocks we like better than Kazia Therapeutics
- What Are Dividend Achievers? An Introduction
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What Do S&P 500 Stocks Tell Investors About the Market?
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.